Company intelligence / Profile preview
Genor Biopharma
- Ownership
- Public · 6998
- Employees
- ~800
- Development stage
- Commercial
Overview
Genor Biopharma has multiple products on the market in China including Herceptin biosimilar (汉曲优/Hanquyou) for HER2+ breast cancer. The company has a robust pipeline of biosimilars and novel biologics in various stages of development from preclinical to commercial.
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Monoclonal antibodiesFusion proteinsRecombinant proteinsBispecific antibodies
- Industry
- Biotech
Drug pipeline
29 assets28 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Genor Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genor Biopharma.